Core Insights - March Biosciences has been awarded a $200,000 G-Rex® Grant to advance the manufacturing of its lead asset, MB-105, a novel CAR-T cell therapy targeting CD5 for T-cell lymphomas [1][5]. Company Developments - The grant will support the development of a scalable cGMP process using the G-Rex bioreactor, aimed at reducing complexity, time, and costs in manufacturing autologous CAR-T products [2][4]. - March Biosciences is focused on overcoming scalability and efficiency barriers in the manufacturing of MB-105, with the support of Wilson Wolf Manufacturing [3][5]. - The G-Rex Grant will facilitate the establishment of a fully integrated CAR-T cell manufacturing process, enhancing the production capabilities for MB-105 and other CAR-T products in development [4][6]. Industry Context - The G-Rex Grant Program, which has awarded nearly 200 grants, aims to advance cell and gene-modified cell therapy (CGT) development and manufacturing, with individual grants worth up to $300,000 [6][8]. - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, indicating its significant role in the industry [8]. - March Biosciences' MB-105 has received U.S. FDA orphan drug designation for treating relapsed/refractory CD5-positive T-cell lymphoma, highlighting its potential in addressing unmet medical needs [5][14].

Core Insights - Bio-Techne Corporation has launched an Early Access Program for a new assay that enables high-resolution spatial visualization of protein interactions within complex tissues, enhancing the understanding of molecular signaling in disease processes [1][2] Group 1: New Assay Development - The new assay is based on Advanced Cell Diagnostics RNAscope™ technology and allows for in situ detection of protein proximity, providing a spatial solution for exploring functional interactions between proteins [1][2] - This technology addresses limitations of conventional methods that often lose spatial fidelity and do not provide localization data, thus offering a clear visual signal at subcellular resolution [2] Group 2: Research Applications - The assay is particularly valuable for research areas where context is crucial, such as immune checkpoint dynamics, bispecific antibodies, and protein interactions at synaptic junctions [2] - Proof-of-concept data and case studies will be presented at the 2025 American Association for Cancer Research (AACR) annual meeting, showcasing the assay's capabilities [3] Group 3: Company Overview - Bio-Techne Corporation is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [4]

MINNEAPOLIS, April 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL. Bio-Techne's booths will feature its oncology research portfolio spanning early discovery, translational research, and cell and gene therapy development.AACR is recognized as one of the world's ...

SCOTTSDALE, Ariz., April 17, 2025 /PRNewswire/ -- Cyber Enviro-Tech, Inc. (OTCQB-CETI) today announced its successful registration with Kuwait Oil Company (KOC), the world's 10th largest oil producer. This milestone represents a major advancement in CETI's global growth strategy. The rigorous registration process, which can span over two years and exceed a million dollars in cost, offers no guarantee of acceptance which makes this achievement particularly noteworthy. As a result, CETI has been invited to bi ...

Core Insights - Bio-Techne (TECH) shares increased by 10.8% to $54.07, following a significant trading volume, contrasting with a 16.5% decline over the past four weeks [1] - The stock's rise is attributed to investor optimism ahead of its fiscal 2025 Q3 financial results, set to be released on May 7 [2] - The company is projected to report quarterly earnings of $0.52 per share, reflecting an 8.3% year-over-year increase, with expected revenues of $316.3 million, a 4.2% increase from the previous year [3] Earnings Estimates and Trends - The consensus EPS estimate for Bio-Techne has remained stable over the last 30 days, indicating that stock price movements may not sustain without changes in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Context - Bio-Techne operates within the Zacks Medical - Biomedical and Genetics industry, where NovoCure (NVCR) also resides, having experienced a 10.3% increase to $16.95, despite a -27.9% return over the past month [4] - NovoCure's consensus EPS estimate has remained unchanged at -$0.47, representing a -30.6% change compared to the previous year, and it currently holds a Zacks Rank of 4 (Sell) [5]

Company Overview - CMB.TECH is a diversified maritime group that owns and operates over 150 seagoing vessels, including crude oil tankers, dry bulk vessels, container ships, chemical tankers, offshore wind vessels, and workboats [3] - The company also provides hydrogen and ammonia fuel to customers, sourced from its own production or third-party producers [3] - CMB.TECH is headquartered in Antwerp, Belgium, with offices across Europe, Asia, the United States, and Africa [3] Financial Reporting - CMB.TECH published its annual report for the year ended December 31, 2024, in accordance with Belgian law, available on its website [1] - The annual report on Form 20-F was submitted to the U.S. Securities and Exchange Commission on April 9, 2025, and can be downloaded from the company's website [2] Stock Information - CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol CMBT [4]

MINNEAPOLIS, April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and protease-free workflows on Leica's BOND RX research staining instrument, further advancing the capabilities of spati ...

Bio-Techne Corporation (TECH) recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa ("EMEA") region. The facility's capacity should enable the company to grow its customer-centric team in the EMEA and support long-term regional growth. Latest Updates From Bio-Techne's Peers In the life sciences research space, Bio-Techne faces competition from some prominent MedTech players. These companies are also making notable developments i ...

Core Insights - Bio-Techne Corporation is opening a new Customer Experience Centre in Düsseldorf, Germany, aimed at enhancing customer engagement across the EMEA region and supporting long-term growth strategies [1][2] - The new facility will feature a state-of-the-art Demonstration Laboratory showcasing Bio-Techne's full instrument portfolio, allowing customers to gain hands-on experience [1] - Düsseldorf was selected for its strong life sciences sector and strategic location, facilitating access to multiple European markets [2] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [3] - The company employs around 3,100 people worldwide and offers a wide range of products that assist in scientific investigations and drug discovery [3] - Recent product innovations include the Leo™ System, which automates western blot assays, and the COMET™ platform, known for its high-throughput tissue profiling capabilities [4]

MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place from March 22-27 in Boston, MA. Advanced Cell Diagn ...